Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 in Overweight or Obesity
NCT07778693Phase 3Not yet recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MWN109 in obesity (4 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoints: Percentage Change from Baseline in Body Weight at 52 weeks and Proportion of Participants Achieving >=5% Body Weight Reduction at 52 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MWN109
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07778693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778693.